Why the study?
Does finerenone in combination with a RAS inhibitor improve safety and efficacy in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy?
Does finerenone in combination with a RAS inhibitor improve safety and efficacy in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy?
This paper describes the rationale and design of the ARTS-DN phase 2b trial evaluating finerenone in patients with type 2 diabetes and diabetic nephropathy.
ARTS-DN is the first phase 2b trial of finerenone in combination with a RAS inhibitor in patients with type 2 diabetes mellitus and a clinical diagnosis of DN.
No takes yet. Share an insight, caveat, or question.
Ruilope et al. (2014) studied this question.